

Special Issue

Solid Tumors, with a Focus on Urological Cancers: From Molecular Mechanisms to Predictive Biomarkers

Message from the Guest Editors

Solid tumors, including urological cancers (e.g., prostate, bladder, and kidney cancers) and other malignancies, remain a significant global health challenge due to their complexity and resistance to current therapies. Central to their development and progression is the tumor microenvironment (TME), a dynamic ecosystem composed of cancer cells, immune infiltrates, stromal components, vasculature, and the extracellular matrix. The TME not only drives tumor initiation, progression, and metastasis but also contributes to immune evasion and therapy resistance, making it a critical area for research and therapeutic innovation. This Special Issue invites submissions of high-quality research covering the molecular mechanisms underlying the development of solid tumors, with a special focus on urological cancers. Contributions exploring TME dynamics, predictive biomarkers, therapeutic innovations, and the application of advanced technologies are particularly welcome. Research on other solid tumor types that aligns with this translational focus is also encouraged.

Guest Editors

Prof. Dr. Linhui Wang

Department of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Dr. Aimin Jiang

Department of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China

Deadline for manuscript submissions

30 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/258736

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)